INTERFERON ALFA-N3
drugOn this page
Also known as .alpha.-interferonsAlferonAlferon nInterferon alpha-n3Leukocyte interferon
Summary
Interferon Alfa-N3 (CHEMBL2109047) is an approved protein; indicated across 2 conditions including hiv infectious disease and severe acute respiratory syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 2 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109047 |
| Name | INTERFERON ALFA-N3 |
| Type | Protein |
| Max phase | 4 |
Also known as: .alpha.-interferons, Alferon, Alferon n, Interferon alfa-n3, Interferon alpha-n3, Leukocyte interferon, INTERFERON ALFA-N3
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | EFO:0000694 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002078 | PHASE1 | COMPLETED | Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection |
| NCT00000844 | Not specified | COMPLETED | A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3 |
| NCT00002012 | Not specified | COMPLETED | Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients |
| NCT00002018 | Not specified | COMPLETED | Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.